Zusammenfassung
Clomethiazol ist chemisch ein Derivat des Thiazol-Anteils des Thiamins (Vitamin B1) mit
-
antikonvulsiven,
-
sedativen,
-
hypnotischen und auch
-
anxiolytischen
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Athen D (1986) Comparative investigation of chlormethiazole and neuroleptic agents in the treatment of alcoholic delirium. Acta Psychiatr Scand 329 (73): 167–170
Athen D, Hippids H, Meyendorf R, Riemer CH, Steiner CH (1977) Ein Vergleich der Wirksamkeit von Neuroleptika und Chlormethiazol bei der Behandlung des Alkoholdelirs. Nervenarzt 48: 528–532
Bayer AJ, Bayer EM, Pathy MSJ, Stoker MJ (1986) A double-blind controlled study of chlormethia- zole and triazolam as hypnotics in the elderly. Acta Psychiatr Scand [Suppl 329] 73: 104–111
Beckmann H, Athen D (1978) Die Therapie des Delirium tremens. Dtsch Med Wochenschr 103: 1427–1428
Bekanntgabe Der Arzneimittelkommission Der DeutSchen Ärzteschaft (1977) Strenge Indikationsstellung für Clomethiazol. Dtsch Ärztebl 74: 1905
Calverley PMA, Carmichael GLM, Scott DB (1984) The effect of chlormethiazole on the hypoxic drive to breathing in normal man. Br J Clin Pharmacol 18: 163–167
Calverley PMA, Carmichael GLM, Scott DB (1987) Die Behandlung des Delirium tremens bei Alkoholentzug. Arzneimittelbrief. Berlin, Jahrgang 21 (125): 97–100
Douglas NJ, White DP, Weil JV et al. (1982) Hypoxic ventilatory response decrease during sleep in normal man. Am Rev Resp Dis 1235: 286–289
Evans J, Lewis SA, Tinker M (1972) Chlormethiazole, sleep and drug withdrawal. Psychol Med 2: 239–247
Feuerlein W (1989) Aktuelle Beiträge zur Definition und Therapie der Alkoholkrankheit. Neuropsychiatrie 3: 7–12
Fischer PA (1977) Intensivbehandlung des Alkoholentzugssyndroms. Diagnostik Intensivther 2: 9–11
Geisler L, Herberg D (1967) Studies on the effect of some commonly used drugs on the excitability of the respiratory centre in man. Therapiewoche 47: 1941–1947
Giacobini E, Salum I (1961) Treatment of delirium tremens. A comparative study of different therapeutic methods in 434 cases. Acta Psychiatr Scand 37: 198–208
Gsell S et al. (1972) Atem-und Herzstillstand unter Distraneurin. Nervenarzt 43: 635
Helbig H (1962) Das tödliche Alkoholdelir. Nervenarzt 33: 221–226
Hoensch HP (1986) Effect of chlormethiazole on the hepatic monooxygenase enzyme system. Acta Psychiatr Scand [Suppl 329] 73: 66–68
Holzbach E, Boiler KE (1978) Die Behandlung des Delirium tremens mit Haldol. Nervenarzt 49: 405–409
Jostell KG (1987) Pharmacokinetics of chlormethiazole in man and influence of altered physiological conditions. Acta Univ Ups, Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 31. Graphic Systems, Stockholm
Jostell KG et al. (1986) The bioavailability and pharmacodynamics of chlormethiazole in healthy young and elderly volunteers: praeliminary findings. Acta Psychiatr Scand [Suppl 329] 73: 32–33
Kalant H, Khanna JM (1986) Metabolic and functional aspects of tolerance to chlormethiazole and cross-tolerance to ethanol in the rat. Acta Psychiatr Scand [Suppl 329] 73: 45–53
Kalant H, Khanna JM, Llewellyn M, Rinkel GJE, Woodworth I (1986) Functional tolerance to chlormethiazole and crosstolerance to ethanol in the rat: importance of test and mode of drug administration. Acta Psychiatr Scand [Suppl 329] 73: 54–65
Keup W (1977) Das Abhängigkeitspotential des Clomethiazol (Distraneurin). Dtsch Arztebl 74: 1902–1905
Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkin-Son GR (1975) The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 55: 347–359
Koo KW, Sax DS, Snider GL (1975) Arterial blood gases and pH during sleep in chronic obstructive pulmonary disease. Am J Med 58: 663–670
Laborit H, Coirault R (1957) L’utilisation en clinique médicale et psychiatrique de l’action hypogéne d’un dérivé du noyau thiazolique de la Vitamine B1. Le S.C.T.Z. Sem Med (Paris) 33: 1704
Laborit H, Coirault R, Damasio R, Guarjard R, Laborit G, Fabrizy P (1957) Sur un type nouveau d’anesthésie chirurgicale et sur e’emploi en thérapeutique d’un dépresseur du cortex cérébral. ( S.C.T.Z. ). Anesth Analg 14: 384
Liljenberg B et al. (1986) The effects of chlormethiazole in EEG recorded sleep in normal elderly volunteers. Acta Psychiatr Scand [Suppl 329] 73: 34–39
Majumdar SK (1978) The effect of chlormethiazole on hepatic microsomal enzymes. Pharmatherapeutica 2: 27–30 (reprint)
Majumdar SK (1981) Effects on the endocrine system of drugs used in treating the ethanol withdrawal syndrome: a survey. Drug Alcohol Depend 7: 379–385
Majumdar SK (1986) The influence of chlormethiazole on the neuroendocrine system in chronic alcoholics. Acta Psychiatr Scand [Suppl 329] 73: 69–72
Marion H, Schneider E (1970) Der Einfluß von Chlormethiazol ( Distraneurin) auf das SchlafElektroencephalogramm nach Alkoholdelir. Pharmakopsychiatr Neuro Psychopharm 3: 233–238
Moore RG, Triggs EJ, Shanks CM, Thomas J (1975a) Pharmacokinetics of chlormethiazole in humans. Eur J Clin Pharmacol 8: 353–357
Moore RG, Robertson AV, Smytm I MP, Thomas J, Vine J (1975b) Metabolism and urinary excretion of chlormethiazole in humans. Xenobiotica 5: 687–696
Nies AS, Shand PG, Wilkinson GR (1976) Altered hepatic blood flow and drug disposition. Clin Pharmacokin 1: 135–155
Ogren SO (1986) Chlormethiazole-mode of action. Acta Psychiatr Scand [Suppl 329] 73: 13–27
Platz W (1981) Therapie medikamentös bedingter deliranter Syndrome, insbesondere bei Clomethiazol- Abhängigkeit. In: Keup W (Hrsg) Behandlung der Sucht und des Mißbrauchs chemischer Stoffe. 4. Wissenschaftliches Symposium der Deutschen Hauptstelle gegen die Suchtgefahren in Tutzing, 1980. Thieme, Stuttgart New York, S 65–73
Platz W (1985) Medikamentöse Therapie bei gerontopsychiatrischen Notfällen. Med Klin 80: 511–513
Pälsson A (1986) The efficacy of early chlormethiazole medication in the prevention of delirium tremens. A retrospective study of the outcome of different drug treatment strategies at the Helsingborg psychiatric clinics, 1975–1980. Acta Psychiatr Scand [Suppl 329] 73: 140–145
Schied HW, Mann K (1989) Die Behandlung des Delirium tremens und des Alkoholentzugssyndroms. In: Schied HW, Heimann H, Mayer K (Hrsg) Der chronische Alkoholismus. Fischer, Stuttgart New York, S 285–300
Schmehling E (1967) Atemdepression nach Distraneurin? Nervenarzt 38: 266–269
Schmidt L (1986) Alkoholkrankheit Alkoholmißbrauch. Kohlhammer, Stuttgart Berlin Köln Mainz
Scott DB (1986) Circulatory and respiratory effects of chlormethiazole. Acta Psychiatr Scand [Suppl 329] 73: 28–31
Stille G (1986) Das Abhängigkeitspotential von Clomethiazol. In: Evans G, Feuerlein W, Glatt MM, Kanowski S, Scott DB (Hrsg) Clomethiazol. Verlag für angewandte Wissenschaften, München, S 103–109
Who Expert Committee on Drug Dependence (1988) Twenty-fourth report. Technical Report Series 761. World Health Organization, Geneva, pp 11–13
Ahrens R (1991) Androcur (Cyproteronacetat) bei Sexualdelinquenz — Nachuntersuchung von untergebrachten psychiatrischen Patienten. Schweiz Arch Neurol Psychiatr 142: 171–188
Bancroft J, Tennent G, Loucas K, Cass J (1974) The control of deviant sexual behaviour by drugs. Br J Psychiatry 125: 310–315
Bhargava AS, Soeger A, Günzel P (1977) Isolation und identification of 15-beta-hydroxy cyproterone acetats as a new metabolite of cyproterone acetate in dog, monkey and man. Steroids 30: 407
Binder S, Roters G, Schultka H (1971) Klinische und experimentell-psychologische Untersuchungen zur Wirkung des Antiandrogens Cyproteronazetat bei erheblich vermindert zurechnungsfähigen und zurechnungsunfähigen Sexualdelinquenten. Nervenarzt 42: 26
Cooper AJ, Ismail AAA, Phanjoo AL, Lone DL (1972) Anti-androgen therapy in deviant hypersexuality. Br J Psychiatry 102: 59
Dorfmann RI (1970) Serum assays and anti-androgens. Biological activity on antiandrogens. Br J Dermatol 82 [Suppl 61: 3–8
Fähndrich E (1974) Cyproteronacetat in der Behandlung von Sexualdeviationen bei Männern. Dtsch Med Wochenschr 99: 234
Herrmann WM, Beach RC (1978) Experimental and clinical data indicating the psychotropic properties of progestogens. Postgraduate Med J 54 [Suppl 2]: 82–87
Hoffet H (1968) Die medizinischen Behandlungsmöglichkeiten von Sexualdelinquenten. Schweiz Z Strafrecht 84: 377
Hoffet H (1969) Neue Wege in der Behandlung von Sexualdelinquenten. Kriminalistik 23: 405
Hoffet H (1980) Die klinische Anwendung von Antiandrogenen in der Psychiatrie. Gynäkologe 13: 33–43
Horn HJ (1971) Der Leidensdruck als Indikationskriterium. Bemerkungen zur “medikamentösen Kastration”. Nervenarzt 42: 312
Itil TM, Cora R, Akpinar S, Herrmann WM, Patter-Son CI (1974) Psychotropic action of sex hormones. Curr Ther Res 16. 11: 1147
Kockott G (1983) Die Behandlung sexueller Delinquenz mit Antiandrogenen. Psychiat Prax 10: 158–164
Laschet U (1970) Ergebnisse neuer medikamentöser Behandlungsmethoden bei Sexualdelinquenten. Kriminolog Gegenwartsfragen 9: 174–179
Laschet U (1988) Die Behandlung männlicher Sexualdeviationen. 20 Jahre Erfahrungen mit Androcur. Vorlesungsreihe Schering, Heft 20
Laschet U, Laschet L (1971) Psychopharmacotherapy of sex offenders with cyproterone acetate. Pharmakopsychiatr Neuro Psychopharmakol 4: 99–104
Laschet U, Laschet L (1978) Ten years cyproterone acetate for the modification of sexual behaviour in men. bga-Berichte 3: 91–96
Menghini P, Ernst K (1991) Die Antiandrogenbehandlung im rückblickenden Urteil von 19 Sexualstraftätern. Nervenarzt 62: 303–307
Micheroli R, Battegay R (1985) Ambulante Behandlung von Sexualdelinquenten mit Cyproteronacetat ( Androcur ). Schweiz Arch Neurol Neurochir Psychiatr 136: 37–58
Mothes C, Lehnert J, Samimi F, Ufer J (1973) Klinische Prüfung von Cyproteronacetat ( Androcur) bei Sexualdeviationen - Gesamtauswertung. Med Mitteilungen 2: 26–39
Neumann F (1977) Normale und gestörte Sexualdifferenzierung. Medizin in unserer Zeit 1: 98–108
Neumann F (1978) Chemie, Biochemie und pharmakologische Grundlagen der Antiandrogene. Dtsch Ärztebl 75: 1633–1640
Neumann F (1986) Pharmacology and clinical uses of cyproteron-acetate. In: Furr BJA, Wakeling AE (eds) Pharmacology and clinical uses of inhibitors of hormone secretion and action. Bailliére Tindall, London Philadelphia Toronto Mexico City Sydney Tokyo Hong Kong, pp 132–159
Neumann F (1989) Möglichkeiten der pharmakodynamischen Beeinflussung des Sexualverhaltens. Symposium Sexualmedizin, Heidelberg
Neumann F, Elger W (1966) Permanent changes in gonadal function and sexual behaviour as a result of early feminization of male rats by treatment with an antiandrogenic steroid. Endokrinologie 50: 209–225
Neumann F, Wiechert R (1984) Die Geschichte von Cyproteronacetat. MPS, Med Pharmazeut Studienges e.V., Mainz. Berichte aus der PharmaForschung, Bd I II
Neumann F, Wiechert R (1988) Das Antiandrogen Cyproteron-acetat. Pharmazie in unserer Zeit 17: 33–50
Neumann F, Elger W, Steinbeck H (1970) Antiandrogens and reproductive development. Phil Trans Roy Soc Lond B 259: 179–184
Neumann F, Schleusener A, Albring M (1978) Pharmacology of antiandrogens. IN: Hammerstein J, Lachnit-Fixson U, Neumann F, Plewig G (eds) Androgenization in women–acne, seborrhoea, androgenetic alopecia and hirsutism. Excerpta Medica, Amsterdam Oxford Princeton, pp 147–192
Neumann F, Schleusener A, Humpel M (1979) Antiandrogene. Gynäkologe 12: 228–242
Ott F, Hoffet H (1968) Beeinflussung von Libido, Potenz und Hodenfunktion durch Antiandrogene. Schweiz Med Wochenschr 98: 1812–1815
Rasch W (1978) Sexuelle Devianz und strafrechtliche Sanktion. In: Füllgraff G, Barbey I (Hrsg) Abschlußbericht der Kommission beim Bundesgesundheitsamt: Stereotaktische Hirnoperationen bei abweichendem Sexualverhalten (bga-Berichte 3 ). D Reimer, Berlin, S 111–114
Rasch W (1986) Forensische Psychiatrie. Kohlhammer, Stuttgart Berlin Köln Mainz
Raspé G (ed) (1972) Schering Symposium über Sexualdeviationen und ihre medikamentöse Behandlung. Life Science Monographs 2. Pergamon Press. Vieweg, Oxford Edinburgh New York Toronto Sydney Braunschweig
Schacher A, el Etreby MF, Neumann F (1984) Einfluß von Cyproteronacetat, Flutamid und Spironolacton auf die Achse Hypothalamus-Hypophyse-Hoden bei Ratten. Akt Urol 15: 218
Sigusch V (1979) Die Behandlung mit Antiandrogenen. Sexualmedizin 8: 13–19
Wiechert R, Neumann F (1965) Gestagene Wirksamkeit von 1-Methyl-und 1,2a-Methylen-Steroiden. Arzneimittelforschung 15: 244–246
Azrin NH, Sisson RW, Meyer SR, Godley M (1982) Alcoholism treatment by disulfiram and com- munity reinforcement therapy. J Behav Ther Exp Psychiatry 13: 105–112
Bartmann U, Fautsch J (1991) Eine Chance für die ambulante Therapie. Psycho 17: 192–202
Bartonicek V, Teisinger J (1962) Effect of tetraethyl thiuram disulphide (disulfiram) on metabolism of trichloro-ethylene in man. Br J Industr Med 19: 216–221
Bilbao JM, Briggs SJ, Gray TA (1984) Filamentous axonopathy in disulfiram neuropathy. Ultrastruct Pathol 7: 295–300
Chick J, Gough K, Falkowski W, Kershaw P, Hore B, Mehta B, Ritson B, Ropner R, Torley D (1992) Disulfiram treatment of alcoholism. Br J Psychiatry 161: 84–89
Christensen JK, Ronsted P, Vaag VH (1984) Side effects after disulfiram. Acta Psychiatr Scand 69: 265–273
Ciraulo DA, Barnhill J, Boxenbaum H (1985) Pharmacokinetic interaction of disulfiram and an- tidepressants. Am J Psychiatry 142: 1373–1374
Coger RW, Dymond AM, Serafetinides EA et al. (1976) Averaged visual evoked response amplitude-intensity slope and symmetry in withdrawal. Biol Psychiatry 11: 435–443
Cushmann P (1986) Sedative drug interactions of clinical importance. In: Galanter M (ed) Alcoholism, vol 4. Plenum Press, New York London
Feuerlein W (1989) Alkoholismus — Mißbrauch und Abhängigkeit, 4. Aufl. G Thieme, Stuttgart
Fischer I (1945) Säregen svampförgiftining. Sv Läk-Tidn 42: 2513–2515
Fuller RK (1988) Disulfiram treatment of alcoholism. In: ROSE RM, BARRET JE (eds) Alcoholism: origins and outcome. Raven Press, New York, pp 237–244
Fuller RK, Roth HP (1979) Disulfiram for the treatment of alcoholism: an evaluation in 128 men. Ann Intern Med 90: 901–904
Fuller RK, Williford WO (1980) Life-table analysis of abstinence in a study evaluating the efficacy of disulfiram. Alcohol Clin Exp Res 4: 298–301
Gill K, Amit Z (1989) Serotonin uptake blockers and voluntary alcohol consumption. A review of recent studies. In: Galanter M (ed) Alcoholism, vol 7. Plenum Press, New York London, pp 225–248
Halo E, Jacobson I (1948) A drug sensitising the organism to ethylalcohol. Lancet 11: 1001–1003
Haubroe K (1980) What we know today about “Antabuse® (Disulfiram)”. Manedsskrift for praktisk Laegegerning 58: 30–40
Iber FL, Lee K, Lacoursiere R, Fuller R (1987) Liver toxicity encoutered in the Veterans Administration trial of disulfiram in alcoholics. Alcohol Clin Res 11: 301–304
Jacobsen E (1967a) Neues über die theoretische Grundlage der Disulfiram-Wirkung. Med Welt 18 (N.F.): 2169–2173
Jacobsen E (1967b) Die Verwendung von Disulfiram (Antabus®). Med Welt 18 (N.F.): 2230–2234
Jaffe JH, Ciraulo DA (1985) Drugs used in the treatment of alcoholism. In: Mendelson JH, Mello NK (eds) The diagnosis and treatment of alcoholism, 2nd ed. McGraw-Hill, New York
Jensen E (1984) A proper use of Antabuse, the Danish model of treatment. Br J Clin Pract [Suppl 36] 38: 2–4
Kitson TM (1977) The disulfiram-ethanol reaction. J Studies Alcohol 38: 96–113
Koelsch F (1914) Über neuartige gewerbliche Erkrankungen in Kalkstickstoffbetrieben. Münch Med Wochenschr 35: 1869–1870
Koivusalo M (1956) Studies on the metabolism of methanol and formaldehyde in the animal organism. Acta Physiol Scand 39 [Suppl 131]
Küfner H, Feuerlein W (1989) In-patient treatment for alcoholism. Springer, Berlin Heidelberg New York Tokyo
Lenz H (1957) Zur Ursache der fehlenden Antabus-Alkohol-Reaktion. Wien Klin Wochenschr 38 /39: 743
Lindros KO, Stowell A, Pikkarainen P, Salaspuro M (1981) The disulfiram (Antabuse) alcohol reaction in male alcoholics: its efficient management by 4-methylpyrazole. Alcohol Clin Exp Res 5: 528–530
Macleod SM, Sellers EM, Giles HG, Billings BJ, Martin PR, Greenblatt DJ, Marshman JA (1978) Interaction of disulfiram with benzodiazepines. Clin Pharmacol Ther 24: 583–589
Mccrady B (1989) Outcomes of family-involved alcoholism treatment. In: Galanter M (ed) Alcoholism, vol 7. Plenum Press, New York London, pp 165–182
Nutt D, Adinoff B, Limoila M (1989) Benzodiazepines in the treatment of alcoholism. In: Galanter M (ed) Alcoholism, vol 7. Plenum Press, New York London, pp 283–313
Pattison EM (1985) The selection of treatment modalities for the alcoholic patient. In: Mendelson JH, Mello NK (eds) The diagnosis and treatment of alcoholism, 2nd ed. McGraw-Hill, New York
Peeke SC, Prael AR, Herning RI et al. (1979) Effect of disulfiram on cognition, subjective response, and cortical event-related alcoholic in nonalcoholic subjects. Alcohol Clin Exp Res 3: 223–229
Perman ES (1962) Effect of ethanol on oxygen uptake and on blood glucose concentration in anesthetized rabbits. Acta Physiol Scand 55: 189–202
Platz WE (1992) Alkoholkriminalität (in Vorbereitung)
Rainey JM (1977) Disulfiram toxicity and carbon disulfide poisoning. Am J Psychiatry 134: 371–378
Robichaud C, Strickler D, Bigelow G, Liebson I (1979) Disulfiram maintenance employee alcoholism treatment: a three-phase evaluation. Behav Ther 14: 618–621
Schmidt L (1986) Alkoholkrankheit and Alkoholmißbrauch. Kohlhammer, Stuttgart
Schuckit MA (1981) Disulfiram (Antabuse) and the treatment of alcoholic men. Adv Alcohol 11: 1–4
Schuckit MA (1985a) Treatment of alcoholism in offices and outpatient settings. In: Mendelson JH, Mello NK (eds) The diagnosis and treatment of alcoholism, 2nd ed. McGraw-Hill, New York
Schuckit MA (1985b) A one-year follow-up of men alcoholics given disulfiram. J Stud Alcohol 46: 191–195
Schuckit MA ( 1985 c) Inpatient and residential approaches to the treatment of alcoholism. In: Mendelson JH, Mello NK (eds) The diagnosis and treatment of alcoholism, 2nd ed. McGraw-Hill, New York
Schuckit MA (1989) Drug and alcohol abuse. Plenum, New York London
Sellers EM, Naranjo CA, Peachey JE (1981) Drugs to decrease alcohol consumtion. N Engl J Med 305: 1255–1262
Staub H (1955) Beiträge zum Antabuse-Problem. Helv Physiol Acta 13: 121–140
Strömme JH, Eldjarn L (1966) Distribution and chemical forms of diethyldithiocarbamate and tetraethylthiuram disulphide ( Disulfiram) in mice in relation to radioprotection. Biochem Pharmacol 15: 287–297
Truitt EB, Duritz G, Morgan AM, Prouty RW (1962) Disulfiram-like actions produced by hypoglycemic sulfonylurea compounds. Q J Stud Alcohol 23: 197–207
Usdin GL, Rond PC, Hinchcliffe JA, Ross WD (1952) The meaning of disulfiram to alcoholics in group psychotherapy. Q J Stud Alcohol 13: 590–599
Williams EE (1937) Effects of alcohol on workers with carbon disulfide. JAMA 109: 1472–1473
Apter A, Van Praag HM, Plutchik R, Sevy S, Korn M, Brown SL (1990) Interrelationships among anxiety, aggression, impulsivity, and mood: a serotonergically linked cluster? Psychiatry Res 32: 191–199
Ball JC, Ross A (1991) (eds) The effectiveness of methadone maintenance treatment. Springer, Berlin Heidelberg New York Tokyo
Balldin JK, Berggren UC, Lindstedt G (1992) Neuroendocrine evidence for reduced dopamine receptor sensitivity in alcoholism. Alcoholism Clin Exp Res 16: 71–74
Barnes DM (1988) The biological triangle of drug addiction. Science 241: 415–417
Baumgarten HG (1991) Neuroanatomie und Neurophysiologie des zentralen 5-HT-Systems. In: Heinrich K, Hippius H, Poldinger W (Hrsg) Serotonin–ein funktioneller Ansatz für die psychiatrische Diagnose und Therapie? Springer, Berlin Heidelberg New York Tokyo, S 17–44
Bergmark A, Oscarsson L (1987) The concept of control and alcoholism. Br J Addict 82: 1203–1212
Bloom FE (1987) Future directions and goals in basic psychopharmacology. In: Meltzer HY (ed) Psychopharmacology. The third generation of progress. Raven Press, New York, pp 1685–1689
Blum K, Briggs AH, Trachtenberg M (1989) Ethanol ingestive behaviour as a function of central neurotransmission. Experientia 45: 444–452
Boning J (1989) Anxiety and dependence–reason or consequence? Psychiat Fen [Suppl] 20: 83–90
Boning J (1991) Zur Neurobiologie und Psychopathologie süchtigen Verhaltens. In: Wanke K, Behringer G (Hrsg) Grundstörungen der Sucht.Springer, Berlin Heidelberg New York Tokyo, S 1–27
Brahen LS, Capone TJ, Capone DM (1988) Naltrexon: lack of effect on liver enzymes. J Clin Pharmacol 28: 64–70
Breese GR, Criswell HE, Mueller RA (1990) Evidence that lack of brain dopamine during development can increase the susceptibility for aggression and self-injurious behaviour by influencing D1-dopamine receptor function. Prog Neuro Psychopharmacol Biol Psychiatry 14: S 65–80
Brewer C, Rezae H, Bailey C (1988) Opioid withdrawal and naltrexone induction in 48–72 hours with minimal dropout, using a modification of the naltrexone-clonidine technique. Br J Psychiatry 153: 340–343
Bronisch F (1990) Alcoholism and depression. Prog Alcohol Res 2: 69–99
Bruno F (1989) Buspirone in the treatment of alcoholic patients. Psychopathology 22: 49–59
Buydens-Branchey L, Branchey MH, Noumair D (1989) Age of alcoholism onset. I. Relationship to psychopathology. II. Relationship to susceptibility to serotonin precursor availability. Arch Gen Psychiatry 46: 225–230, 231–236
Cadoret RJ, Troughton E, Bagford J, Woodworth G (1990) Genetic and environmental factors in adoptee antisocial personality. Eur Arch Psychiatr Neurol Sci 239: 231–240
Cloninger CR (1987) Neurogenetic adaptive mechanisms in alcoholism. Science 236: 410–416
Cloninger CR, Sigvardsson S, Bohman M (1988) Childhood personality predicts alcohol abuse in young adults. Alcoholism Clin Exp Res 12: 494–505
Collingridge GL, Davies SN (1989) NMDA receptors and long-term potentiation in the hippocampus. In: Watkins JC, Collingridge GL (eds) The Nmda receptor. IRL Press, Oxford, pp 123–136
Costall B, Jones BJ, Kelly ME, Naylor RJ, Onaivi ES, Tyres MB (1990) Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol Biochem Behav 36: 339–344
Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. PNAS 85: 5274–5278
Dongier M, Vachon L, Schwartz G (1991) Bromocriptine in the treatment of alcohol dependence. Alcoholism Clin Exp Res 15: 970–977
Dorus W, Ostrow DG, Anton R et al. (1989) Lithium therapy of depressed and nondepressed alcoholics. JAMA 262: 1646–1652
Fawcett J, Clark DC, Aagesen CA, Pisani VD, Tilkin JM, Sellers D, Mcguire M, Gibbons RD (1987) A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry 44: 248–256
Finlay JM, Damsma G, Fibiger HC (1992) Benzodiazepine-induced decreases in extracellular concentrations of dopamine in the nucleus accumbens after acute and repeated administration. Psychopharmacology 106: 202–208
Friessem DH, Täschner KL (1991) Codein and Dihydrocodein als Ausweich-and Ersatzdrogen. Fortschr Neurol Psychiat 59: 164–169
Garcia-Alonso F, Gutierrez M, San L et al. (1989) A multicenter study to introduce naltrexone for opiate dependence in Spain. Drug Alcohol Depend 23: 117–121
Gawin FH, Kleber HD (1984) Cocaine abuse treatment: open pilot trial with desipramine and lithium carbonate. Arch Gen Psychiatry 42: 903–910
Gawin FH, Allen D, Humblestone B (1989) Outpatient treatment of “crack” cocaine smoking flupentixol decanoate a preliminary report. Arch Gen Psychiatry 46: 322–325
George DT, Adinoff B, Ravitz B, Nutt DJ, Dejong J, Berrettini W, Mefford IN, Costa E, Linnoila M (1990a) A cerebrospinal fluid study of the pathophysiology of panic disorder associated with alcoholism. Acta Psychiatr Scand 82: 1–7
George DT, Nun DJ, Dwyer BA, Linnoila M (1990b) Alcoholism and panic disorder: is the comorbidity more than coincidence? Acta Psychiatr Scand 81: 97–107
Ginzburg HM (1986) Naltrexone: its clinical utility. Adv Alcohol Subst Abuse 5: 83–101
Goldstein A (1989) (ed) Molecular and cellular aspects of the drug addictions. Springer, Berlin Heidelberg New York Tokyo
Graeff FL (1986) 5-Hydroxytryptamine, aversion, and anxiety. Behav Brain Sci 9: 339–340
Gronbladh L, Ohlund LS, Gunne LM (1990) Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand 82: 223–227
Hartmann F, Poirier MF, Bourdel MC, Loo H, Le-Comte JM, Schwartz JC (1991) Comparison of acetorphan with clonidine for opiate withdrawal symptoms. Am J Psychiatry 148: 627–629
Havemann-Reinecke U (1991) Sucht–zur neuro-biologischen Grundlagenforschung in der Bundesrepublik. In: Materialien zur Gesundheitsforschung. Schriftreihe zum Programm der Bundesregierung Forschung und Entwicklung im Dienste der Gesundheit (Hrsg) Suchtforschung: Bestandsaufnahme und Analyse des Forschungsbedarfs. Bonn (Bd 19 ), S 33–49
Hawkes CH (1992) Endorphins: the basis of pleasure? J Neurol Neurosurg Psychiatry 55: 247–250
Herz A, Shippenberg TS (1989) Neurochemical aspects of addiction: opioids and other drugs of abuse. In: Goldstein A (ed) Molecular and cellular aspects of the drug addiction. Springer, Berlin Heidelberg New York Tokyo, pp 111–142
Hubbard RL, Rachal JV, Craddock SG, Cavanaugh ER (1984) Treatment outcome prospective study (TOPS): client characteristics and behaviours before, during, and after treatment. In: TIMs FM, Ludford JP (eds) Drug abuse treatment evaluation: strategies, progress and prospects. NIDA, Rockville, MD, pp 42–68 (Monograph series 51 )
Hutson PH, Bristow LJ, Thorn L, Tricklebank MD (1991) R-(+)-HA-966, a glycine/NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine. Br J Pharmacol 103: 2037–2044
Irwin M, Schuckit M, Smith TL (1990) Clinical importance of age at onset in type 1 and type 2 primary alcoholics. Arch Gen Psychiatry 47: 320–324
Johnston AL, Thevos AK, Randall CL, Anton RF (1991) Increased severity of alcohol withdrawal in in-patient alcoholics with a co-existing anxiety diagnosis. Br J Addict 86: 719–725
Kahn RS, Wetzler S (1991) m-chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 30: 1139–1166
Kalant H (1989) The nature of addiction: an analysis of the problem. In: Goldstein A (ed) Molecular and cellular aspects of the drug addictions. Springer, Berlin Heidelberg New York Tokyo, pp 1–28
Keup W (1990) Eignung für Methadon-Erhaltungs-programme in einer Zufallsstichprobe von Drogenabhängigen. Suchtgefahren 36: 243–249
Keup W (1991) Naltrexon–Einsatz für Opiatab- hängige. Arzneimitteltherapie 5: 129–132
Knorring AL V, Bohman M, Knorring L V, Oreland L (1985) Platelet MAO activity as a biological marker in subgroups of alcoholism. Acta Psychiatr Scand 72: 51–58
Knorring AL V, Hallman J, Knorring L v, Oreland L (1991) Platelet monoamine oxidase activity in type I and type 2 alcoholism. Alcohol Alcoholism 26: 409–416
Knorring L V, Knorring AL v, Smigan L, Lindberg Y, Edholm M (1987) Personality traits in subtypes of alcoholics. J Stud Alcohol 48: 523–527
Kosten TA, Kosten TR (1991) Pharmacological blocking agents for treating substance abuse. J Nerv Ment Dis 179: 583–592
Kosten TR, Kleber HD, Morgan C (1989) Role of opioid antagonists in treating intravenous cocain abuse. Life Sci 44: 887–892
Kosten TR, Morgan C, Kleber HD (1991) Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse 17: 119–128
Kryspin-Exner K (1983) Psychopharmakotherpie bei Abhängigkeitsprozessen von Alkohol, Medikamenten und Drogen. In: Langer G, Hei-Mann H (Hrsg) Psychopharmaka. Grundlagen und Therapie. Springer, Wien New York, S 491–514
Krystal JH, Leaf PJ, Bruce ML, Charney DS (1992) Effects of age and alcoholism on the prevalence of panic disorder. Acta Psychiatr Scand 85: 77–82
Kuschinsky K (1981) Psychic dependence on opioids: mediated by dopaminergic mechanisms in the striatum? TINS 11: 287–289
Kushner MG, Kenneth MA, Sher J, Beitman BD (1990) The relation between alcohol problems and the anxiety disorders. Am J Psychiatry 147: 685–695
Lee MA, Meltzer HY (1991) Neuroendocrine responses to serotonergic agents in alcoholics. Biol Psychiatry 30: 1017–1030
Lesch OM, Walter H, Bonte W, Grunberger J, Mu-Salek M, Sprung R (1991) Etiology of subgroups in chronic alcoholism and different mechanisms in transmitter systems. In: Palmer TN (ed) Alcoholism–a molecular perspective. Nato, Life Sciences 206: 137–152
Limson R, Goldman D, Roy A, Lamparski D, Ravitz B, Adinoff B, Linnoila M (1991) Personality and cerebrospinal fluid monoamine metabolites in alcoholics and controls. Arch Gen Psychiatry 48: 437–441
Linnoila M, Eckardt M, Durcan M, Lister R, Martin P (1987) Interactions of serotonin with ethanol: clinical and animal studies. Psychopharmacol Bull 23: 452–457
Liskow BI, Goodwin DW (1987) Pharmacological treatment of alcohol intoxication, withdrawal and dependence: a critical review. J Stud Alcohol 48: 356–370
Loimer N, Lenz K, Schmid R, Presslich O (1991) Technique for greatly shortening the transition form methadone to naltrexone maintenance of patients addicted to opiates. Am J Psychiatry 148: 933–935
Malka R, Loo H, Ganry H, Souche A, Marey C, Kamoun A (1992) Long-term administration of tianeptine in depressed patients after alcohol withdrawal. Br J Psychiatry 160: 66–71
Mason BJ, Kocsis JH (1991) Desipramine treatment of alcoholism. Psychopharmacol Bull 27: 155–161
Meert TF, Janssen PAJ (1991) Ritanserin, a new therapeutic approach for drug abuse. Part 1. Effects on alcohol. Drug Dev Res 24: 235–249
Meert TF, Janssen PAJ (1992a) Ritanserin, a new therapeutic approach for drug abuse. Part 2. Effects on cocaine. Drug Dev Res 25: 39–53
Meert TF, Janssen PAJ (1992b) Ritanserin, a new therapeutic approach for drug abuse. Part 3. Effects on fentanyl and sucrose. Drug Dev Res 25: 55–66
Meyer RE (1989) Prospects for a rational pharmacotherapy of alcoholism. J Clin Psychiatry 50: 403–412
Meyers R, Beil H (1989) Ambulante Behandlung von Alkohol-and Drogenabhängigen. Munch Med Wochenschr 131: 489–493
Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17: 263–287
Miller FT, Busch F, Hertz-Tanenbaum J (1989) Drug abuse in schizophrenia and bipolar disorder. Am J Drug Alcohol Abuse 15: 291–295
Miller NS, Ries RK (1991) Drug and alcohol dependence and psychiatric populations: the need for diagnosis, intervention and training. Compr Psychiatry 32: 268–276
Möller HG, Nowak K, Kuschinsky K (1987) Conditioning of pre-and postsynaptic behavioural responses to the dopamine receptor agonist apomorphine in rats. Psychopharmacology 91: 50–55
Moody CA, Spear LP (1992) Ontogenetic differences in the psychopharmacological responses to separate and combined stimulation of D, and D2 dopamine receptors during the neonatal to weanling age period. Psychopharmacology 106: 161–168
Morris RGM, Davis S, Butcher SP (1989) The role of NMDA receptors In learning and memory. In: Watkins JC, Collingridge GL (eds) The NMDA receptor. IRL Press, Oxford New York Tokyo, pp 137–152
Myers RD (1989) Isoquinolines, (3-carbolines and alcohol drinking: involvement of opioid and dopaminergic mechanisms. Experientia 45: 436–443
Nace EP, Davis GW, Gaspari JP (1991) Axis II comorbidity in substance abusers. Am J Psychiatry 148: 118–120
Noble EP, Blum K, Ritchie T, Montgomery A, Sheri-Dan PJ (1991) Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 48: 648–654
Ollat H, Parvez H, Parvez S (1988) Alcohol and central neurotransmission. Neurochem Int 13: 275–300
Olivier B, Mos J, Rasmussen D (1990) Behavioural pharmacology of the serenic, eltoprazine. Drug Metab Drug Interact 8: 31–83
Parsian A, Todd RD, Devor EJ, O’malley KL, Suarez BK, Reich T, Cloninger RC (1991) Alcoholism and alleles of the human D2 dopamine receptor locus. Arch Gen Psychiatry 48: 655–663
Peralta V, Cuesta MJ (1992) Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand 85: 127–130
Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediatet by K opiate receptors. Science 233: 774–776
Pietraszek MH, Urano T, Sumioshi K, Serizawa K, Takahashi S, Takada Y, Takada A (1991) Alcohol-induced depression: involvement of serotonin. Alcohol Aloholism 26: 155–159
Post RM, Susan R, Weiss B (1992) Sensitization, kindling, and carbamazepine: an update on their implications for the course of affective illness. Pharmacopsychiatry 25: 41–43
Presslich O, Loimer N, Aschauer G, Fodor G, Pfersmann D, Müller K, Pakesch G, Lieber A (1989) Fraktionierter Opiatentzug mit Tiaprid and Naloxon, ein neuer Therapieansatz. Psychiat Prax 16: 179–181
Regier LDA, Farmer ME, Rae DS et al. (1990) Co-morbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area ( ECA) study. JAMA 264: 2511–2518
Resnick RB, Resnick E, Galanter M (1991) Buprenorphine responders: a diagnostic subgroup of heroin addicts? Prog Neuro Psychopharmacol Biol Psychiatry 15: 531–538
Rezvani AH, Grady DR, Janowsky DS (1991) Effect of calcium-channel blockers on alcohol consumption in alcohol-drinking monkeys. Alcohol Alcoholism 26: 161–167
Robbins SJ, Ehrman RN (1992) Designing studies of drug conditioning in humans. Psychopharmacology 106: 143–153
Ross HE, Glaser FB, Stiasny S (1988) Sex differences in the prevalence of psychiatric disorders in patients with alcohol and drug problems. Br J Addict 83: 1179–1192
Rou Renberg O (1988) Das Belohnungssystem des Gehirn. In: Gehirn und Nervensystem. Spektrum der Wissenschaft. Verlagsgemeinschaft Weinheim, S 161–167
Roy A, Virkkunen M, Linnoila M (1987) Reduced central serotonin turnover in a subgroup of alcoholism. Prog Neuro Psychopharmacol Biol Psychiatry 11: 173–177
Roy A, Dejong J, Lamparski D, George T, Linnoila M (1991) Depression among alcoholics. Arch Gen Psychiatry 48: 428–432
San L, Pomarol G, Peri JM, Olle JM, Cami J (1991) Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 86: 983–990
Scherbaum N, Gastpar M (1991) Die Substitution mit Methadon als Therapieansatz in der Behandlung Opiatabhängiger. Nervenarzt 62: 529–535
Schmidt LG, Rommelspacher H (1990) Biologische Marker des Alkoholismus. Nervenarzt 61: 140–147
Schrappe O (1980) Toxikomanie. In: Peters UH (Hrsg) Die Psychologie des 20. Jahrhunderts, Bd X. Ergebnisse für die Medizin ( 2 ). Psychiatrie. Kindler, Zürich, S 849–868
Schuckit MA (1986) Genetic and clinical implications of alcoholism and affective disorder. Am J Psychiatry 143: 140–147
Schuckit MA (1987) Biology of risk for alcoholism. In: Meltzer HY (ed) Psychopharmacology. The third generation of progress. Raven Press, New York, pp 1527–1533
Schuckit MA (1989) Drug and alcohol abuse. A clinical guide to diagnosis and treatment. Plenum, New York
Segest E, Mygind O (1990) The influence of prolonged stable methadone maintenance treatment on mortality and employment: an 8-year follow-up. Int J Addict 25: 53–63
Sellis SB (1981) Follow-up and treatment outcome. In: Lo’inson JH, Ruiz P (eds) Substance abuse: clinical problems and perspectives. Williams and Wilkins, Baltimore London, pp 783–800
Shaw GK, Majumdar SK, Waller S, Macgarvie J, Dunn G (1987) Tiapride in the long-term ma- nagement of alcoholics of anxious or depres- sive temperament. Br J Pschiatry 150: 164–168
Shippenberg TS, Bals-Kubik R, Huber A, Herz A (1991) Neuroanatomical substrates mediating the aversive effects of D1—dopamine receptor antagonists. Psychopharmacology 103: 209–214
Snyder SH (1987) Molecular strategies in neuropsychopharmacology: old and new. In: Meltzer HY (ed) Psychopharmacology. The third generation of progress. Raven Press, New York, pp 17–21
Stastny D, Potter M (1991) Alcohol abuse by patients undergoing methadone treatment programm. Br J Addict 86: 307–310
Steketee JD, Sorg BA, Kalivas PW (1992) The role of the nucleus accumbens in sensitization to drugs of abuse. Neuro Psychopharmacol Biol Psychiatry 16: 237–246
Strian F, Zieglgänzberger W, Holsboer F (1991) Neurobiologische Forschungsstrategien zur Alkoholkrankheit. In: Materialien zur Gesundheitsforschung. Schriftreihe zum Programm der Bundesregierung Forschung und Entwicklung im dienste der Gesundheit (Hrsg) Suchtforschung: Bestandsaufnahme und Analyse des Forschungsbedarfs. Bonn (Bd 19 ), S 50–64
Sullivan JL, Baenziger JC, Wagner DL, Rauscher FP, Nurnbrger JI, Holmes JS (1990) Platelet MAO in subtypes of alcoholism. Biol Psychiatry 27: 911–922
Szmigielski A, Zalewska-Kaszubska J (1991) Cooperation between D,— and D2—dopamine receptors in the nucleus accumbens. Neuropharmacology 30: 259–266
Taschner KL (1991) Brauchen wir Methadonsubstitutionsprogramme? Nervenarzt: 62: 524–528
Tollefson GD (1989) Serotonin and alcohol: interrelationships. Psychopathology 22 [Suppl]: 37–48
Tollefson GD, Lancaster SP, Montague-Clouse J (1991) The association of buspirone and its metabolite 1—pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmacol Bull 27: 163–170
Topel H (1990) Perspektiven der Alkoholismus-Forschung der 90er Jahre. Suchtgefahren 36: 91–96
Turner E, Ewing J, Shilling P, Smith TL, Irwin M, Schuckit M, Kelsoe JR (1992) Lack of association between an RFLP near the D2dopamine receptor gene and severe alcoholism. Biol Psychiatry 31: 285–290
Trudeau LE, Aragon CMG, Amit Z (1991) Involvement of endogenous opioid mechanisms in the interaction between stress and ethanol. Psychopharmacology 103: 425–429
Udego L, Grenhoff J, Svensson TH (1989) Ritanserin, a 5—HT, receptor antagonist, activates mid-brain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45–50
Vining E, Kosten TR, Kleber HD (1988) Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict 83: 567–575
Vogel WH, Netter P (1989) Effect of ethanol and stress on plasma catecholamines and their relation to changes in emotional state and performance. Alcoholism Clin Exp Res 13: 284–290
Watson SJ, Trujillo KA, Herman JP, AKIL H (1989) Neuroanatomical and neurochemical substrates of drug-seeking behaviour: overview and future directions. In: Goldstein A (ed) Molecular and cellular aspects of the drug addictions. Springer, Berlin Heidelberg New York Tokyo, pp 29–91
Weddington WW, Brown BS, Haertzen CA, Hess JM, Mahaffey JR, Kolar AF, Jaffe JH (1991) Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug Alcohol Abuse 17: 137–152
Weiss RD, Mirin SM (1989) Tricyclic antidepressants in the treatment of alcoholism and drug abuse. J Clin Psychiatry 50: 4–9
Wikler A (ed) (1980) Opioid dependence. Mechanisms and treatment. Plenum Press, New York London
Wise RA (1987) The role of reward pathways in the development of drug dependence. Pharmacol Ther 35: 227–263
Wittchen HU, Hand I, Hecht H (1989) Prävalenz, Komorbidität und Schweregrad von Angststörungen. Ergebnisse der Münchner Followup-Studie ( MFS ). Z KIM Psychol 18: 117–133
Birmanns B, Clarenbach P (1989) Effect of serotonin receptor antagonists on sleep and sleep related release of HGH, prolactin and cortisol. In: Wauquier A et al. (eds) Slow wave sleep: physiological, pathophysiological and functional aspects. Raven, New York, pp 235–242
Campbell M, Adams P, Small AM, Curren EL, Overall JE, Anderson LT, Lynch N, Perry R (1988) Efficacy and safety of fenfluramine in autistic children. J Am Acad Child Adolesc Psychiatry 4: 434–439
Ceulemans DLS, Hoppenbrouwers MLJA, Gelders YG, Ryntjens AJM (1985) The influence of ritanse- rin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 18: 303–305
Cook EH JR, Leventhal BL, Freedman DX (1988) Free serotonin plasma: autistic children and their first-degree relatives. Biol Psychiatry 24: 488–491
Curzon G (1988) Serotonergic mechanism of depression. Clin Neuropharmacol 11 [Suppl 2]: 11–20
Den Boer JA (1989) Serotonergic mechanism in anxiety disorders. An inquiry into serotonergic function in panic disorder. Pharmaceutisch Weekblad Scientific edition 11: 103–104
Doerish CT (1987) Brain 5-HT, receptors and anxiety. In: DouxisH CT et al. (eds) Brain 5-HT„ receptors. Ellis Howard, Chichester, pp 261–277
Gelders Y (1989) Ritanserin: an original thymosthenic, 4th ed. Janssen Research Foundation, Beerse
Gelernter J, Kammen DP (1988) Schizophrenia: instability in norepinephrine, serotonin, and gamma-aminobutyric acid systems. Int Rev Neurobiol 29: 309–347
Glennon RA (1990) Serotonin receptors: clinical implications. Neurosci Biobehav Rev 14: 35–47
Janssen PAJ (1987) Does ritanserin, a potent serotonin S2-antagonist, restore energetic functions during the night? J R Soc Med 80: 409–4413
Leibowitz SF, Weiss GF, Shor-Posner G (1988) Hypothalamic serotonin: pharmacological, biochemical, and behavioral analyses of its feeding-suppressive action. Clin Neuropharmacol 11 [Suppl 11: 51–71
Leonard BE (1988) Pharmacological effects of serotonin reuptake inhibitors. J Clin Psychiatry 49: 12–17
Leysen JE, Van Gompel P, Gommeren W, Woesten-Borghs R, Janssen PAJ (1986) Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with serotonin-S2 antagonists: ritanserin and setoperone. Psychopharmacology 88: 434 444
Marfk GJ, Li A, Seiden LS (1989) Selective 5hydroxytryptamine2 antagonists have antidepressant-like effects on differential-reinforcement of low rate 72-S schedule. J Pharmacol Exp Ther 250: 52–59
Mcbride PA, Anderson GM, Hertzig ME, Sweeny JA (1989) Serotonergic responsivity in male young adults with autistic disorder. Arch Gen Psychiatry 46: 213–221
Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T, Mizol Y, Tanaka C (1986) Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 21: 1407–1414
Paiva T, Arriaga F, Wauquier A, Lara E, Largo R, Leitao JN (1989) Changes in sleep disturbances of dysthymic patients induced by ritanserin. In: Wauquier A et al. (eds) Slow wave sleep: physiological, pathophysiological and functional aspects. Raven, New York, pp 217–234
Pastel RH (1988) Effects of LY53857, a selective 5-HT2 antagonist, on sleep in the rat. Soc Neurosci Abstr 14: 1307
Realmuto GM, August GJ, Garfinkel BD (1989) Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 9: 122–125
Reynolds GP, Arnold L, Rossor MN, Iversen LL, Mountjoy CQ, Roth M (1984) Reduced binding of (3H)ketanserin to cortical 5-HT2 receptors in senile dementia of the Alzheimer type. Neurosci Lett 44: 47–51
Sanders-Bush E, Breeding M, Roznoski M (1987) 5HT2 binding sites after mianserin: comparison of loss of sites and brain levels of drug. Eur J Pharmacol 133: 199–204
Silver H, Blacker M, Weller MPI, Lerer B (1989) Treatment of chronic schizophrenia with cyproheptadine. Biol Psychiatry 25: 502–504
Stanley M, Mann JJ (1983) Increased serotonin-2 binding sites in the frontal cortex of suicide victims. Lancet is 214–216
Tricklebank MD (1989) Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol Sci 10: 129
Ugedo L, Grenhoff J, Svensson TH (1989) Ritanserin, a 5-HT2 receptor antagonist, activates mid-brain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45–50
Watling KJ (1989) 5-HT3 receptor agonists and antagonists. Neurotransmission 5: 1–4
Akerman KEO, Heinonen E (1983) Qualitative measurement of cytosolic calciumion concentration within isolated guinea-pig nerve endings using entrapped arsenazo. Biochem Biophys Acta 732: 111–121
Allen GS, Goss CJ, French LA, Chou SN (1976) Cerebral arterial spasm. Part 5. In vitro contractile activity of vasoactive agents including human cerebrospinal fluid on human basilar and anterior cerebral arteries. J Neurosurg 6: 63–70
Allen GS, Ahn HS, Preziosi TJ et al. (1983) Cerebral arterial spasm–a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 308: 619–624
Alps BJ, Calder C, Wilson A (1983) The beneficial effect of nicardipine compared with nifedipine and verapamil in limiting myocardial infarct size in baboons. Arzneimittelforschung 33: 868–876
Amery WK, Cares LI, Aerts WJL (1985) Flunarizine, a calcium entry blocker in migraine prophylaxis. Headache 25: 249–254
Ames A III, Wright RL, Kowada M, Thurston JM, Majno G (1968) Cerebral ischemia. II. The noreflow phenomenon. Am J Pathol 52: 437–453
Anthony M, Hinterberger H, Lance JW (1968) Studies of serotonin metabolism in migraine. Proc Austr Assoc Neurol 5: 109–112
Asplund K, Eriksson S (1987) Scandinavian Stroke Study Group: multicenter trial of hemodilution in acute ischemic stroke. In: Hartmann A, Kuschinsky W (eds) Cerebral ischemia and hemorheology. Springer, Berlin Heidelberg New York Tokyo, pp 472–486
Astrup J, Siesjö BK, Symon L (1981) Thresholds in cerebral ischemia: the ischemic penumbra. Stroke 12: 723–725
Auer LM (1981) Pial arterial vasodilatation by intravenous nimodipine in cats. Drug Res 31: 1423–1425
Auer ML (1983) Cerebrovascular activity of the calcium antagonist nimodipine. In: Reivich M, Hurtig S (eds) Cerebrovascular diseases. Raven Press, New York, pp 375–384
Ban TA, Morey L, Aguglia E, Azzarelli O, Balsano F, Marigliano V, Caglieris N, Steriicchio M, Capurso A, Tomasi NA, Crepaldi G, Volpe D, Palmieri G, Ambrosi G, Polli E, Cortellaro M, Zanussi C, Froldi M (1990) Nimodipine in the treatment of old age dementias. Prog Neuro Psychopharmacol Biol Psychiatry 14: 525–551
Barrett JN, Magelby KL, Pallotta BS (1982) Properties of single calcium activated potassium channels in cultured rat muscle. J Physiol 331: 211–230
Blass JP, Zemcov A (1984) Alzheimer disease: a metabolic systems degeneration. Neurochem Pathol 2: 103–114
Blaustein MP (1974) Interrelationship between sodium and calcium fluxes across cell membranes. Rev Physiol Biochem Pharmacol 70: 33–82
Böker DK, Solymosi L, Wassmann H (1985) Immediate postangiographic intraarterial treatment of cerebral vasospasm after subarachnoid hemorrhage with nimodipine. Neurochirurgi-ca 28: 118–120
Boni G, Manzioni GC, Matrucci N, Baldrati A, Farina S, Cassabgi F, Decarolis P, Nappi G Flunarizine in common migraine: Italian cooperative trial. II. Long-term follow-up. Cephalalgia 2: 155–158
Bourke RS, Kimelberg HG (1975) The effect of HCO3 on the swelling and ion uptake of monkey cerebral cortex under conditions of raised extracellular potassium. J Neurochem 25: 323–328
Brandt L, Anderson KE, Edvinsson L, Ljunggren B (1981) Effects of extracellular calcium and of calcium antagonists on the contractile responses of isolated human pial and mesenteric arteries. J Cereb Blood Flow Metab I: 339–347
Branston NM, Strong AJ, Symon L (1977) Extracellular potassium activity, evoked potential and tissue blood flow: relationships during progressive ischaemia in baboon cerebral cortex. J Neurol Sci 32: 305–321
Brody IA (1969) Muscle contracture induced by exercise. N Engl J Med 281: 187–192
Campbell AK (1983) Intracellular calcium: its universal role as regulator. Wiley, New York
Carbone E, Lux HD (1984) A low voltage-activated, fully inactivating Ca channel in vertebrate sensory neurones. Nature 310: 501–502
Castillo J Del, Katz B (1954) Quantal components of the end plat potential. J Physiol 124: 560–573
Cheung WY (1982) Calmodulin: an overview. Fed Proc 41: 2253–2257
Caongdon PJ, Forsrre WI (1979) Migraine in childhood: a study of 300 children. Dev Med Child Neurol 21: 209–216
Cortes R, Supavilai P, Karobath M, Palacios JM (1984) Calcium antagonist binding sites in the rat brain: quantitative autoradiographic mapping using the 1,4—dihydropyridines (3H)PN 200–110 and (3H)PY 108–068. J Neural Transm 60: 169–197
Crompton MR (1964) The pathogenesis of cerebral infarction following the rupture of cerebral berry aneurysms. Brain 87: 491–510
Danon MJ, Karpati G, Charuk J, Holland P (1988) Sarcoplasmatic reticulum adenosine triphos- phate deficiency with probably autosomal dominant inheritance. Neurology 38: 812–814
Delorenzo RJ (1983) Caclium-calmodulin protein phosphorylation in neuronal transmission: a molecular approach to neuronal excitability and anticonvulsant drug action. Adv Neurol 34: 311–323
Demopoulos HB, Flamm ES, Pietronigro DD, Selig-Man ML (1980) The free radical pathology and the microcirculation in the major central ner- vous disorders. Acta Physiol Scand 492: 91–119
Deshmukh SV, Meyer JS (1977) Cyclic change in platelet dynamics and the pathogenesis and prophylaxis of migraine. Headache 17: 101–108
Dick DJ, Gardner-Medwin D, Gates PG, Gibson M, Walls TJ (1986) A trial of flunarizine in the treatment of Duchenne muscular dystrophy. Muscle Nerve 9: 349–354
Dunlap K, Fischbach GD (1981) Neurotransmitters decrease the calcium conductance activated by depolarization of embryonic chick sensory neurones. J Physiol 317: 519–535
Eckert R, Chad JE (1984) Inactivation of Ca chan- nels. Prog Biophys Mol Bio144: 215–267
Elbaz P, Haguenauer JP, Muler H, Portmann M (1986) Activite therapeutique d’un inhibiteur de la surcharge calcique, la flunarizine, dans les troubles vestibulaires: etude a double insu contra placebo. ORL 35: 301–308
Ell J, Gresty M (1983) The effects of the “vestibular sedative” drug flunarizine upon the vestibular and oculomotor systems. J Neurol Neurosurg Psychiatry 46: 716–724
Eppich C, Barnes CA, Baldwin J (1985) 3,4-Dia-minopyridine improves spatial working me- mory but not spatial reference memory in aged rats. Soc Neurosci Abstr 11: 724
Fisher CM, Robertson GH, Olemann G (1984) Cerebral vasospasm with ruptured saccular aneurysm — the clinical manifestation. Neurosurgery 1: 245–248
Flaim SF (1982) Comparative pharmacology of calciumblockers based on studies of vascular smooth muscle. In: Flaim SF, Zeus R (eds) Calcium blockers: mechanism of action and clinical applications. Urban & Schwarzenberg, Baltimore, pp 155–178
Fleckenstein A (1977) Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17: 149–166
Fraser RAR, Stein MM, Barrett RE, Pool JL (1970) Noradrenergic mediation of experimental cerebrovascular spasm. Stroke 1: 356–362
Freedman SB, Dawson G, Villereal ML, Miller RJ (1984) Identification and characterization of voltage-sensitive calcium channels in neuronal clonal cell lines. J Neurosci 4: 1453–1467
Freeman GB, Gibson GE (1986) Selective alteration of neurotransmitter release with aging. Soc Neurosci Abstr 12: 271
Frenken CWGM, Nuijten STM (1984) Flunarizine, a new preventive approach in migraine. Clin Neurol Neurosurg 86: 17–20
Fijisawa A, Matdsumoto M, Matsltyama T, Ueda H, Wanaka W, Yoneda S, Kimura K, Kamada T (1986) The effect of the calcium antagonist nimodipine on the gerbil model of experimental cerebral ischemia. Stroke 17: 748–752
Gaab RM, Rode C-P, Schakel EH, Haubitz I, Bock-Horn J, Brawanski A (1985) Zum Einfluß des Ca-Antagonisten Nimodipin auf die globale and regionale Hirndurchblutung. Klin Wochenschr 83: 8–15
Garb MR, Hollerhage HG, Zumkeller M, Trost HA (1987) The effect of the Ca antagonist nimodipine on cerebral blood flow autoregulation. J Cereb Blood Flow Metab 7: 170
Gallant EM, Foldes FF, Rempel WE, Gronert GA (1985) Verapamil is not a therapeutic adjunct to dantrolene in porcine malignant hyperthermia. Anaesth Anal 64: 601–606
Gardos G (1958) The function of calcium in the potassium permeability of human erythrocytes. Biochem Biophys Acta 30: 653–654
Garruto RM, Fukatsu R, Yanagihara R, Gajdusek DC, Hook G, Fiori CE (1984) Imaging of calcium and aluminium in neurofibrillary tangle-bearing neurons in Parkinsonism-dementia of Guam. Proc Natl Acad Sci USA 81: 1875–1879
Gelmers HJ (1982) Effect of nimodipine (Bay-9736) on postischaemic cerebrovascular reactivity, as revealed by measuring regional cerebral blood flow (rCBF). Acta Neurochir (Wien) 63: 283–290
Gelmers HJ (1983) Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. Headache 23: 106–109
Gelmers HJ, Gorter K, De Weerdt CJ, Wiezer HJ (1988) A controlled trial of nimodipine in acu- te ischemic stroke. N Engl J Med 318: 203–207
Ginsberg MD, Mela L, Wrobel Kuhl K, Reivich M (1977) Mitochondrial metabolism following bilateral cerebral ischemia in the gerbil. Ann Neurol 1: 519–527
Goldensohn ES, Purpura DP (1963) Intracellular potentials of cortical neurons during focal epileptogenic discharges. Science 139: 840–842
Gould RJ, Murphy KMM, Snyder SH (1982) Autoradiographic visualization of (3H)-nitrendipine binding sites in rat brain: localization to synaptic zones. Eur J Pharmacol 82: 517–519
Gould RJ, Murphy KMM, Reynolds U, Snyder SH (1984) Calcium channel blockade: possible explanation for thioridazine’s peripheral side effects. Am J Psychiatry 141: 352–357
Greenberg DA, Carpenter CL, Cooper EC (1985) Stimulation of calcium uptake in PC12 cells by the dihydropyridine agonist BAY K 8644. J Neurochem 45: 990–993
Gronert GA, Mou J, Lee J (1988) Aetiology of malignant hyperthermia. Anaesth 60: 253–267
Grubb RL, Raichle ME, Eichlin JO, Gado MH (1977) Effect of subarachnoid hemorrhage on cere- bral blood volume, blood flow and oxygen utilisation in humans. J Neurosurg 46: 446–453
Guerrero JR, Martin SS (1984) Verapamil: full spectrum calcium channel blocking agent: an overview. Med Res Rev 4: 87–109
Harper AM, Braigen L, Karda S (1981) Effect of the calcium antagonist, nimodipine, in cerebral blood flow and metabolism in the primate. J Cereb Blood Flow Metab 1: 349–356
Harris RJ, Symon L, Branston NM, Bayan M (1981) Changes in extracellular calcium activity in cerebral ischaemia. J Cereb Blood Flow Me-tab 1: 203–209
Harris RJ, Branston MM, Symon L, Bayhan M, Wat-Son A (1982) The effect of a calcium antagonist, nimodipine, upon physiological responses of the cerebral vasculature and its possible influence upon focal cerebral ischemia. Stroke 13: 759–766
Hartmann A (1987) Die Bedeutung der Rheologie für zerebrale Durchblutungsstörungen. Akt Neurol 14: 35–41
Hartmann A (1987) Die Hämodilution beim zerebralen Insult. Akt Neurol 14: 42–49
Hartmann A (1988) Die Gehirndurchblutung bei der Migräne. In: Soyka D (Hrsg) Klinische Kopfschmerzsyndrome. Fischer, Stuttgart New York, S 33–44
Havanka-Kanniainen H, Hokkanen E, Myllyka VV (1985) Efficacy of nimodipine in the prophylaxis of migraine. Cephalgia 5: 39–43
Heffez DS, Passoneau JV (1985) Effect of nimodipine on cerebral metabolism during ischemia and recirculation in the mongolian gerbil. J Cereb Blood Flow Metab 5: 523–528
Heiss WD (1983) Flow thresholds of functional and morphological damage of brain tissue. Stroke 14: 329–331
Hess P, Landsman JB, Tsien RW (1984) Different modes of Ca channel gating behavior favoured by dihydropyridine Ca agonist and antagonists. Nature 311: 538–544
Hilles B (1984) Ionic channels of excitable membranes. Sinauer Associates, Sunderland Mass
Hofferberth B (1986) Calcium entry blockers in the treatment of vertebro-basilar insufficiency. Eur Neurol 25: 80–85
Holmes B, Brogden RN, Heel C, Speight TM, AVERY GS (1984) Flunarizine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 27: 6 44
Hossman KA, Paschen W, Csiby L (1983) Relation-ship between calcium accumulation and re- covery of cat brain after prolonged cerebral ischemia. J Cereb Blood Flow Metab 3: 346–353
Jacoss MB (1983) Diltiazem and akathisia. Ann Intern Med 99: 794–795
Kahan A, Weber S, Amor B, Guerin F, Degeorges M (1983) Nifedipine in the treatment of migraine in patients with Raynaud’s phenomenon. N Engl J Med 308: 1102–1103
Kalls P (1977) Uptake and release of calcium in rabbit vagus nerve. Pflügers Arch 326: 1–14
Karpati G, Charuk J, Carpenter S, Jablecki C, Hol-Land P (1986) Myopathy caused by a deficiency of Ca“ ATPase in sarcoplasmatic reticulum ( Brody’s disease ). Ann Neurol 20: 38–49
Kassell NF, Sasaki T, Colohan ART, Nayar G (1985) Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 16: 562–572
Kazda S, Garthoff B, Krause HP, Schlossmann K (1982) Cerebral vascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments. Arzneimittelforschung 2: 331–338
Kimball RW, Goodmann MA (1961) Effects of reserpine on amino acid excretion in patients with vascular headaches. Neurology (Minneapolis) 11: 116
Kur A, Elder B, Ruiz-Funes HP, Buchwald M, Grin-Stein (1985) The free cytoplasmatic Ca“-levels in Duchenne muscular dystrophy lymphocytes. Muscle Nerve 8: 317–320
Koos WT, Pernezky A, Auer LM, Böker DB, Gaab MR, Jaschke H, Kostron H, Meinig G, Muizellar JP, Van Der Werft AJM, Seibert HK, Ulrich F, Sprung C (1985) Nimodipine treatment of ischemic neurological deficits due in cerebral vasospasms after subarachnoid hemorrhage. Neurochirurgica 28: 114–117
Lauritzen M, Olsen J (1984) Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. Brain 107: 447–461
Lauritzen M, Skyhoj Olsen T, Lassen NA, Paulson OB (1983) Changes in regional cerebral blood flow during the course of classical migraine attacks. Ann Neurol 13: 633–641
Lead AAP (1944) Spreading depression of activity in cerebral cortex. J Neurophysiol 7: 359–390
Lee KS, Tsien RW (1986) Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature 302: 790–794
Lee JA, Watson A, Boothby G (1986) Calcium antagonists in the prevention of motion sickness. Aviat Space Environ Med 57: 45–48
Lehmenkühler A (1979) Interrelationship between CD potentials, potassium activity, pO2 and pCO2 in the cerebral cortex of the rat. In: Speckmann EJ, Caspers H (eds) Origin of cerebral field potentials. Thieme, Stuttgart, pp 49–59
Lewis JG (1983) Adverse reactions to calcium antagonists. Drugs 25: 196–222
Li CL, Van Buren JM (1972) Micro-electrode recordings in the brain of man with particular reference to epilepsy and dyskinesia. In: Somjen GG (ed) Neurophysiology studied in man. Excerpta Medica, Amsterdam, pp 49–63
Ljunggren B, Brandt L, Saeveland H, Nilsson PE et al. (1984) Outcome in 60 consecutive patients treated with early aneurysm operation and intravenous nimodipine. J Neurosurg 67: 864 873
Lopez JR, Allen PD, Alamo L, Jones D, Sreter FA (1988) Myoplasmic free Ca“ during a malignant hypertheramia episode in swine. Muscle Nerve 11: 82–88
Louis P (1981) A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache 21: 235–239
Louis P, Sperings ELH (1982) Comparison of flunarizine (Sibelium) and pizotifen (Sandomigran) in migraine treatment: a double-blind study. Cephalgia 2: 197–203
Lüllmann H, Peters TH (1977) Plasmalemmal calcium in cardiac excitation-contradiction coupling. Clin Exp Pharmacol Physiol 4: 49–57
Lüllmann H, Peters TH, Preuner J (1983) Role of the plasmalemma for calcium homeostasis and for excitation-contraction coupling in cardiac musle. In: Drake N, Holland S, Noble M (eds) Cardiac metabolism. Wiley, Chichester, pp 1–18
Lux HD, Hofmeier G (1982) Properties of calcium-and voltage-activated potassium current in helix pomatia neurons. Pflügers Arch 394: 61–59
Markley HG, Cheronis JCD, Piepho RW (1984) Verapamil in prophylactic therapy of migraine. Neurology 34: 973–976
Matsumuto H, Ajmone Marsan C (1964) Cortical cellular phenomena in experimental epilepsy: interictal manifestations. Exp Neurol 9: 286–304
Matthews EK (1986) Calcium and membrane permeability. Br Med Bull 42: 391–397
Meech RW (1978) Calcium-dependent potassium activation in nervous tissues. Ann Rev Biophys Bioeng 7: 1–18
Mendenopoulos G, Manafi T, Logothesis 1, Bostant-Joroulou S (1985) Flunarizine in the prevention of classical migraine. A placebo controlled evaluation. Cephalalgia 5: 31–37
Meyer EM, Baker SP, Crews FT, Larsen K (1985) Aging and acetylcholine-release from cortical synaptosomal and atrial minces. Soc Neurosci Abstr 11: 980
Meyer FB, Anderson RE, Sundt TM Jr, Yaksh TL (1986) Intracellular brain pH, indicator tissue perfusion, electroencephalography, and histology in severe and moderate focal cortical ischemia in the rabbit. J Cereb Blood Flow Metab 1: 190–191
Meyer FB, Anderson RE, Sund TM Jr, Sharbrough FW (1986) Selective central nervous system calcium channel blockers–a new class of anticonvulsive agents. Mayo Clin Press 61: 239–247
Meyer JS, Hardenberg J (1983) Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headache. Headache 23: 266–277
Micieli O, Trucco M, Agostinis C, Macuso A, Papalia F, Sinforiani E (1985) Nimodipine vs. pizotifen in common migraine: results of a double blind cross-over trial. Cephalagia 5: 532–533
Miller RJ (1985) How many types of calcium channels exist in neurones? Trends Neurosci 8: 45–47
Miller JR (1987) Multiple calcium channels and neuronal function. Science 235: 46–52
Mohamed AA, Gotch O, Graham DI, Osborne KA, Mcculloch J, Mendelow AD, Teasdale GM, Harper AM (1985) Effect of pretreatment with the calcium antagonist nimodipine on local cerebral blood flow and histopathology after middle cerebral artery occlusion. Ann Neurol 18: 705–711
Mongini T, Ghigo D, Doriguzzi C, Bussolino F, Pascarmona G, Pollo B, Schiffer D, Bosia A (1988) Free cytoplasmatic Ca“ at rest and after cholinergic stimulus is increased in cultured muscle cells from Duchenne muscular dystrophy patients. Neurology 38: 476–480
Moxley RT, Brooke MH, Fenichel GM, Mendell JR, Griggs RC, Miller JP, Province MA, Patterson V (1987) Clinical investigation in Duchenne dystrophy. VI. Double-blind controlled trial of nifedipine Muscle Nerve 10: 22–33
Murphy KMM, Gould RJ, Largent BL, Snyder SH (1983) A unitary mechanism of calcium antagonist drug action. Proc Natl Acad Sci USA 80: 860–864
Murphy SN, Miller RJ (1988) A glutamate receptor regulates Cat+ mobilization in hippocampal neurons. Proc Natl Acad Sci USA 85: 8737–8741
Newberg LA, Steen PA, Milde JH, Michenfelder JD (1984) Failure of flunarizine to improve cerebral blood flow or neurologic recovery in a canine model of complete cerebral ischemia. Stroke 13: 666–671
Nishizuka Y (1984) Turnover of inositol phospholipide and signal transduction. Science 225: 1365–1370
Nowycky MC, Fox AP, Tsien RW (1985) Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature 316: 440–443
Olesen J, Larsen B, Lauritzen M (1981) Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 9: 344–352
Oosterveld D (1982) Flunarizine in vertigo. A double-blind placebo-controlled crossover evaluation of a constant-dose schedule. ORL 44: 72–80
Oosterveld WJ (1974) Vestibular pharmacology of flunarizine compared to that of cinnarizine. ORL 36: 157–164
Overweg J, Ashton D, DE Beukelaar F, Binnie Wau-Quier A (1986) Add-on therapy in epilepsy with calcium entry blockers. Eur Neurol 25: 93–101
Paskin NH (1981) Pharmacology of migraine. Ann Rev Pharmacol Toxicol 21: 463–478
Peerless SJ, Kassell NF, Komatsu K, Hunter IG (1980) Cerebral vasospasm: acute proliferative vasculopathy? II. Morphology. In: WILKINS RH (ed) Cerebral arterial spasm. Williams & Wilkins, Baltimore, pp 88–96
Pelletieri L, Carlson CA, Lindholm L (1981) Is the vasospasm following subarachnoid hemorrhage an immunoreactive disease? Experientia 15: 1170–1171
Pennefather K, Lancaster B, Adams PR, Nicoll RA (1986) Two distinct Ca-dependent K currents in bullfrog sympathetic ganglion cells. Proc Natl Acad Sci USA 82: 3040–3044
Peroutka SJ, Allen GS (1983) Calcium-channel antagonist binding sited labeled by 3H-nimodipine in human brain. J Neurosurg 59: 933–937
Peterson C, Gibson GE (1983) Aging and 3,4—diaminopyridine alter synaptosomal calcium uptake. J Biol Chem 258: 11482–11485
Peterson C, Goldman JE (1986) Alterations in calcium content and biochemical processses during aging and Alzheimer disease. Proc Natl Acad Sci USA 83: 2758–2762
Peterson C, Ratan RR, Shelanski ML, Goldman JE (1986) Cytosolic free calcium and cell spreading decreases in fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci USA 83: 7999–8001
Prentki M, Biden TJ, Janjic D, Irvine RF, Berridge MJ, Wdllheim CB (1984) Rapid mobilization of Ca“’ from rat insulinoma microsomes by ionositol-1,4,5—triphosphate. Nature 309: 562–564
Rascol A, Montastruc JL, Rascol O (1985) Flunarizine versus pizotifen: a double blind study in the prophylaxes of migraine. Cephalalgia 5: 542
Rasmussen H, Waismann DM (1983) Modulation of cell function in the calcium messenger system. Rev Physiol Biochem Pharmacol 95: 111–148
Reynolds IL Gould RJ, Snyder SH (1984) Loperamide: blockade of calcium channels as a mechanism for antidiarrheal effects. J Pharmacol Exp Ther 231: 628–632
Roy MW, Dempsey RJ, Meyer KL, Donaldson DL, Tibbs PA, Young AB (1985) Effects of verapamil and diltiazem on acute stroke in cats. J Neurosurg 63: 929–936
Ryan US (1983) Endothelial cells and inflammation. Clin Lab Med 3: 577–599
Sakai F, Meyer JS (1978) Regional cerebral hemodynamics during migraine and cluster headaches measured by the 133—Xe inhalation method. Headache 18: 122–132
Scherer H, Schmidtmayer E, Hirche H (1978) Die Wirkung von Bencyclan, Flunarizin and Naftridrofuryl auf den Nystagmus eines kalorischen Dauerreizes. Laryngol Rhinol Otol 57: 773–798
Schwartz AC (1985) Neurological recovery after cardiac arrest: clinical feasibility trial of calcium blockers. Am J Emerg Med 3: 1–10
Seiler R, Grolimund P, Weber M (1988) Effect of nimodipine on the CO2 reactivity of patients with aneurysmatil subarachnoid hemorrhage. International Workshop: Cerebral Ischemia and Calcium. Springer, Berlin Heidelberg New York Tokyo
Shader RI, Dimascio A (1970) Psychotropic drug side effects: clinical and theoretical perspectives. Williams & Wilkins, Baltimore
Sharbrough FW, Messick JM JR, Sundt TM Jr (1973) Correlation of continuous electroencephalograms with cerebral blood flow measurements during carotid endarterectomy. Stroke 4: 674–683
Shearman GT (1989) Effect of NMDA antagonist MK-801 in animal models of focal and global cerebral ischemia. In: Ginsberg MD, Dietrich WD (eds) Cerebrovascular diseases. 16th Princetone Conference. Raven Press, New York, pp 73–78
Siesjö BK (1982) Lactic acidosis in the brain: occurrence, triggering mechanisms and pathophysiological importance. Ciba Found Symp 87: 77–100
Siesjö BK (1984) Cerebral circulation and metabolism. J Neurosurg 60: 883–908
Siesjö BK, Wieloch T (1985) Molecular mechanisms of ischemic brain damage: Cat..-related events. In: Plum P, Pulsinelli L (eds) Cerebro-vascular disease. 13th Research Conference, Princetone. Raven Press, New York, pp 187–197
Skinho JE (1973) Hemodynamic studies within the brain during migraine. Arch Neurol (Chicago) 29: 95–98
Smith R, Schwartz A (1984) Diltiazem prophylaxis in refractory migraine. N Engl J Med 310: 1327–1328
Solaro RJ (1982) The role of calcium in the concentration of the heart. In: Flaim SF, Zelis R (eds) Calcium blockers. Urban & Schwarzenberg, Baltimore, pp 21–36
Solomon GD, Steel JG, Spaccavento LJ (1983) Verapamil prophylaxes of migraine: a double-blind, placebocontrolled study. JAMA 250: 2500–2502
Somlyo AV, Bond M, Somlyo AP, Scarpa A (1985) Inositol triphosphate-induced calcium relea- se and contraction in vascular smooth muscle. Proc Natl Acad Sci USA 82: 5231–5235
Sorge F, Desimone R, Marano E, Orefice G, Carrieri P (1985) Efficacy of flunarizine in the pro- phylaxis of migraine in children. Cephalalgia 5: 172
Staessen AJ (1977) Treatment of circulatory disturbances with flunarizine and cinnarizine. VASA 6: 59–71
Stanfield PR (1986) Voltage-dependent calcium-channels of escitable membranes. Br Med Bull 42: 359–367
Steen PA, Newberg LA, Milde JH, Michenfelder JD (1983) Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischemia in the dog. J Cereb Blood Flow Metab 3: 38–43
Strong AJ, Tomlinson BE, Venables GS, Gibson G, Hardy JA (1983) The cortical ischaemic penumbra associated wirth occlusion of the middle cerebral artery in the cat. 2. Studies of histopathology, water content, and in vivo neurotransmitter uptake. J Cereb Blood Flow Metab 3: 97–108
Summers WK, Majovski LV, Marsh GM, Takichi K, Kling A (1986) Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheimer type. N Engl J Med 315: 1241–1245
Suzuki J, Kodama N, Yosjimoto, Mizoi K (1982) Ultraearly surgery of intracranial aneurysms. Acta Neurochir 83: 186–191
Symon L, Ackermann R, Bull JWD et al. (1972) The use of the xenon clearance method in subarachnoid hemorrhage. Post-operative studies with clinical and angiography correlation. Eur Neurol 8: 8–14
Symon L, Branston NM, Strong AJ, Hope TD (1977) The concept of thresholds of ischaemia in relation to brain structure and function. J Clin Pathol 30: 149–154
Taneda M (1982) Effect of early operation for ruptured aneurysms on prevention of delayed ischemic symptoms. J Neurosurg 57: 622–627
Teasdale G, Pickard J, Shaw D, Illingworth R (1989) Treatment of subarachnoid hemorrhage with calcium-antagonist: large randomized controlled trial. In: Hartmann A, Kuschinski W (eds) Cerebral ischemia and calcium. Springer, Berlin Heidelberg New York Tokyo
Thesleff S (1981) Aminopyridines and synaptic transmission. Neuroscience 5: 1413–1419
Theunissen EJJM, Huvgen PLM, Nicolasen MGM (1986) Flunarizine treatment in dizzy patients with vestibular hyperactivity and hyperventilation. ORL 48: 203–208
Turner JS (1977) The dizzy patient: diagnosis and treatments. Drugs 13: 382–387
Vanhouite PM, Paoletti R (1987) The Who classification of calcium antagonists. TIPS 8: 4–5
Vermeulen M, Lindsy KW, Murray GD, Gheahf, Hijdra A, Muizelaar JP, Schannong M, Teasdale GM, Van Grevel H, Van Gijn J (1984) Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med 311: 432–437
Voldby B, Peterson OF, Buhl M, Jakobsen P, Oster-Gaard R (1984) Reversal of cerebral arterial spasm by intrathecal administration of a calcium antagonist (nimodipine). Acta Neurochir (Wien) 70: 243–254
Weir BA (1980) The incidence and onset of vasospasm after subarachnoid hemorrhage from ruptured aneurysm. In: Wilkins RH (ed) Cerebral arterial spasm. Williams & Wilkins, Baltimore, pp 302–305
Welsh FA, O’connor MJ, Marcy VR, Spatacco AJ, Johns RL (1982) Factors limiting regeneration of ATP following temporary ischemia in cat brain. Stroke 13: 234–242
Wesseling H, Agoston S, Van Dam GB, Pasma J, De Wrr DJ, Havinga H (1984) Effects of 4-aminopyridine in elderly patients with Alzheimer’s disease. N Engl J Med 310: 988–989
White BC, Gadzinski DS, Hoehner PJ, Krone C, Hoener T, White DJ, Trombley JH (1982) Effect of flunarizine on canine cerebral cortical blood flow and vascular resistance post cardiac arrest. Ann Emerg Med 11: 119–126
White RP (1979) Multiple origins of cerebral vasospasm. In: Price TR, Nelson E (eds) Cerebro-vascular diseases. Raven Press, New York, pp 307–319
Wieloch T, Siesjö BK (1982) Ischemic brain injury: the importance of calcium, lipolytic activities, and free fatty acids. Pathol Biol (Paris) 30: 269–277
Wiernsperger N, Gyax P, Hofmann A (1984) A calcium antagonist PY 108–068: demonstration of its efficacy in various types of experimental brain ischemia. Stroke 15: 670–683
Wiill, OW, Walden J, Speckmann EJ, Elger CE (1983) Reduction of penicillin-induced paroxysmal depolarization shifts of rat cerebral cortex by intracellular injection of calcium channel blokker. Neurosci Lett 14: 405–407
Wolff GH (1983) Headache and other head pain. Oxford University Press, New York
Zahlmann F, Perloff JK, Durant NN, Campion DS (1983) Acute respiratory failure following intravenous verapamil in Duchenne muscular dystrophy. Am Heart J 3: 104–105
Acevedo AG, Smith JK (1988) Adverse reaction to caffeine in ECT. Am J Psychiatry 145: 529–530
Acevedo AMA (1986) Drug evaluations. Saunders, Philadelphia, pp 324–325
Aranda JV, Gorman W, Bergsteinsson H, Gunn T (1977) Efficacy of caffeine in treatment of apnea in the low — birth weight infant. J Pediatr 90: 467–472
Arnold LE, Christopher J, Huestis R, Smeltzer DJ (1978) Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction. Am J Psychiatry 35: 463–473
Barone JJ, Roberts HR (1984) Human consumption of caffeine. In: Dews P (ed) Caffeine. Springer, Berlin Heidelberg New York, pp 59–73
Beach CA, Mays DC, Guiler RC, Jacober CH, Ger-Ber N (1986) Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics. Clin Pharmacol Ther 39: 265–270
Becker AB, Simons KJ, Gillespie CA, Simons FER (1984) The bronchodilator effects and pharmakokinetics of caffeine in asthma. N Engl J Med 310: 743–746
Berkowitz BA, Spector S, Wool W (1971) The interaction of caffeine, theophylline and theobromine with monoaminoxidase inhibitors. Eur J Pharmacol 16: 315
Blanchard J, Sawers SJA (1983) The absolute bio-availability of caffeine in man. Eur J Clin Pharmacol 24: 93–98
Bonati M, Garattini S (1984) Interspecies comparison of caffeine disposition. In: Dews P (ed) Caffeine. Springer, Berlin Heidelberg New York, pp 48–56
Boulenger JP, Salem N, Marangos PJ, Uhde TW (1987) Plasma adenosine levels: measurement in humans and relationship to the anxiogenic effects of caffeine. Psychiatr Res 21: 247–255
Curatolo PW, Robertson D (1983) The health consequences of caffeine. Ann Intern Med 98: 641–653
Debas HT, Cohen MM, Holubitsky IB, Harrison RC (1971) Caffeine-stimulated gastric acid and pepsin secretion: dose-response studies. Scand J Gastroenterol 6: 453–457
Deckert J, Gleiter CH (1989) Adenosinergic psychopharmaceuticals. TIPS 10: 99–100
Deckert J, Gleiter CH (1990) Adenosinergic psychopharmaceuticals: just an extra cup of coffee? J Psychopharmacol 4: 183–187
Defreitas B, Schwartz G (1979) Effects of caffeine in chronic psychiatric patients. Am J Psychiatry 136: 1337–1338
Dobmeyer DJ, Stine RA, Leier CV, Greenberg R, Schaal SF (1983) The arrhythmogenic effects of caffeine in human beings. N Engl J Med 308: 814–816
Eichler O (1976) Atmung und Atemwege. In: Eichler O (Hrsg) Kaffee und Coffein. Springer, Berlin Heidelberg New York, S 171–173
Ellinwood EH, Rockwell WJK (1988) Central nervous system stimulants and anorectic agents. In: Dukes Mng (ed) Meyler’s side effects of drugs. Elsevier, Amsterdam, pp 1–3
Estler CJ (1982) Caffeine. In: Hoffmeister F, Stille G (eds) Handbook of experimental pharma- cology, vol 55/III. Psychotropic agents. Sprin- ger, Berlin Heidelberg New York, pp 369–389
Estler FDA (1977) Over-the-counter drugs: establishment of monograph for OTC internal analgesic, antipyretic and antirheumatic products. Federal Register 42: 35439–35487
File SE, Bond AJ, Lister RG (1982) Interaction between effects of caffeine and lorazepam in performance tests and self-ratings. J Clin Psychopharmacol 2: 102–106
Fulgraf G (1976) Niere und Nierenfunktion. In: Eichler O (Hrsg) Kaffee und Coffein. Springer, Berlin Heidelberg New York, S 171–173
Gleiter CH, Deckert J, Nurr DJ (1988) Changes in caffeine seizure threshold after electroconvulsive shock. Psychopharmacology 95: 544–545
Gleiter CH, Deckert J, Nuit DJ, Marangos PJ (1989) Electroconvulsive shock ( ECS) and the adenosine neuromodulatory system. J Neurochem 52: 641–646
Goldstein A, Kaizer S, Warren R (1965) Psychotropic effects of caffeine in man. II. Alertness, psychomotor coordination and mood. J Pharmacol Exp Ther 150: 146–151
Greden JF (1981) Caffeinism and caffeine withdrawal. In: Lowinson JH, Ruiz P (eds) Substance abuse. Williams & Wilkins, Baltimore, pp 274–286
Griffiths RR, Woodson PP (1988) Caffeine physical dependence: a review of human and laboratory animal studies. Psychopharmacology 94: 437–451
Haas S, Beckmann H (1983) Psychopharmakotherapie bei (psychotischen) Erregungszuständen. In: Langer G, Heimann H (Hrsg) Psychopharmaka. Springer, Wien New York, S 437–446
Hinkle PE, Coffey CE, Weiner RD, Cress RN, Chri Stison C (1987) Use of caffeine to lengthen seizures in ECT. Am J Psychiatry 144: 1143–1148
Hoeldtke RD, Stephen TC, Hughes JD, Polansky M (1986) Treatment of orthostatic hypotension with dihydroergotamine and caffeine. Ann Intern Med 105: 168–172
Kalow W (1985) Variabilty of caffeine metabolism in humans. Arzneimittelforschung/Drug Res 35: 319–324
Karacan I, Thornby JI, Anch AM, Booth GH, Wil-Liams RL, Salis MA (1976) Dose related sleep disturbances induce by coffee and caffeine. Clin Pharmacol Ther 20: 682–689
Klinz C, Biesold KH (1990) Familiäre paroxysmale dystone Choreoathetose. Nervenarzt 61: 507–509
Laska EM, Sunshine A, Müller F, Elvers WB, Siegel C, Rubin A (1984) Caffeine as an analgesic adjuvant. J Am Med Assoc 251: 1711–1733
Lee MA, Flegel P, Greden JF, Cameron OG (1988) Anxiogenic effects of caffeine on panic and depressed patients. Am J Psychiatry 145: 632–635
Lucas PB, Pickar D, Kelsoe J, Rapaport M, Pato C, Hommer D (1990) Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 28: 35–40
Nagesh RV, Murphy KA (1988) Caffeine poisening treated by hemoperfusion. Am J Kidney Dis 12: 316–318
Onrot J, Goldberg MR, Biaggoni I, Hollister AS, Kincaid D, Robertson D (1985) Hemodynamic and humoral effects of caffeine in autonomic failure. N Engl J Med 313: 549–555
Onrot J, Shaheen O, Biaggioni I, Goldberg MR, Feely J, Wilkinson GR, Hollister AS, Robertson D (1986) Reduction of liver plasma flow by caffeine and theophylline. Clin Pharmacol Ther 40: 506–510
Price KR, Fligner DJ (1990) Treatment of caffeine toxicity with esmolol. Ann Emerg Med 19: 44 46
Rall TW (1990) Drugs used in the treatment of asthma. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P (eds) Goodman and Gilman’s the pharmacological basis of therapeutics, 8th ed. Pergamon, New York, pp 618–637
Reynolds JEF (ed) (1989) Martindale, the extra pharmacopeia, 29th ed. The Pharmaceutical Press, London, pp 1522–1524
Robertson D, Frölich JC, Carr RK, Watson JT, Hollifield JW, Shand DG, Oates JA (1978) Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med 298: 181–186
Schingnitz G, Küfner-Mühl U, Ensinger H, Lehr E (1991) A novel xanthine derivative for treatment of cognitive deficits. Biol Psychiatry 29: 6945
Schnackenberg RC (1973) Caffeine as a substitute for schedule II stimulants in hyperkinetic children. Am J Psychiatry 130: 796–798
Schroder-Rosenstock K (1990) Kaffeekonsum —Ein medizinisches Problem? Münch Med Wochenschr 132: 158–159
Sechzer PH, Abel L (1978) Postspinal anesthesia headache treated with coffeine. Curr Ther Res 24: 307–312
Shapira B, Lerer B, Gilboa B, Drexler H, Kugelmass S, Calev A (1987) Facilitation of ECT by caffeine pretreatment. Am J Psychiatry 144: 1199–1202
Snyder SH (1984) Adenosine as a mediator of the behavioral effects of caffeine. In: DEWS PB (ed) Caffeine. Springer, Berlin Heidelberg New York Tokyo, pp 129–141
Sobotka TJ (1989) Neurobehavioral effects of prenatal caffeine. Ann NY Acad Sci 562: 327–339
Somani SM, Gupta P (1988) Caffeine: a new look at an age-old drug. Int J Clin Pharmacol Toxicol 26: 521–533
Strubelt O (1976) Endokrines System. In: Eichler O (Hrsg) Kaffee und Coffein. Springer, Berlin Heidelberg New York, S 287–296
Strubelt O (1986) Kaffee und Coffein. Dtsch Apotheker Z 38: 2025–2032
Weidner K (1961) Schlaflosigkeit: Versuch mit Kaffee. Selecta 3: 10
Weir RL, Hruska RE (1983) Interaction between methylxanthines and the benzodiazepine receptor. Arch Int Pharmacodyn 254: 42–48
Zenglein R (1975) Behandlung der Migräne. Dtsch Med Wochenschr 100: 557–559
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Wien
About this chapter
Cite this chapter
Platz, W.E. et al. (1992). Sonstige Psychopharmaka. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3793-2_5
Download citation
DOI: https://doi.org/10.1007/978-3-7091-3793-2_5
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-3794-9
Online ISBN: 978-3-7091-3793-2
eBook Packages: Springer Book Archive